Browsing: Modernas

Conditions

Moderna’s mFlusiva Approved as First mRNA

By 0

The Food and Drug Administration (FDA) has approved mFlusiva®, the first mRNA-based influenza vaccine, for adults aged 50 years and older. For persons aged 65 years and older, the vaccine received accelerated approval based on immune responses; continued approval in this age group is contingent upon verification and description of clinical benefit in a confirmatory…